SV

Street Verdict

Analyst Scorecard

LENSKART · NSE

Lenskart Solutions Limited

₹744.35

+0.36% (+₹2.7)

Prev. close

₹741.65

Volume

32,60,264

Delivery %

75.7%

As of

20 Nov 2026

Price history

₹744.35+₹115.95 (+18.45%) · 3M
18 Aug 2026 → 20 Nov 2026
64066068070072074018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

4 analyst stances · last 90 days · one per analyst

Trackable

2 · 2 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

2 · 2 bull / 0 neutral / 0 bear

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (4)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 4 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Lenskart Solutions Limited

Lenskart Solutions Limited, a technology-driven eyewear company, engages in designing, manufacturing, branding, and retailing of eyewear products in India, Japan, Southeast Asia, the Middle East, and internationally. Its products include prescription eyeglasses, sunglasses, goggles, screen glasses, and other products, such as contact lenses and eyewear accessories, including frames for men, women, and kids. The company also engages in lens manufacturing, lens edging, lens design, frame design, frame manufacturing, and delivery. It operates as a direct-to-consumer company that designs and sells a wide range of eyewear products under the Lenskart and Owndays brands; and sub brands, including John Jacobs, Vincent Chase, Hooper, Lenskart Air, Hustlr, LPL, and Meller. It sells its products through online and offline channels, such as retail stores, websites, mobile applications, and other channels. The company also owns and operates eyewear retail stores in India and provides home eye check-up services. Lenskart Solutions Limited was incorporated in 2008 and is based in Gurugram, India.

Details

Sector

Healthcare

Industry

Medical Instruments & Supplies

CEO

Mr. Peyush Bansal

Headquarters

Gurugram

Employees

19,201

Key stats

Market cap

₹1.23 L Cr

P/E ratio (TTM)

191.9

Dividend yield

0.00%

EPS (TTM)

₹3.70

Beta (1Y · daily vs NIFTY 50)

0.53

Shares float

75.52 Cr

EPS · quarter ended Jun 2026

₹1.28

Financial Performance

01 · Financials

-5000 Cr0 Cr5000 Cr10000 Cr₹0%2%4%6%FY21FY22FY23FY24FY25FY26
RevenueNet incomeNet income ÷ revenue

EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21, FY22, FY23 and FY24 (revenue was nil or not reported).

02 · Earnings Per Share (EPS)

0123₹FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%0%100%200%FY21FY22FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

Left off as not meaningful (growth from a very small base, beyond ±400%): Fixed assets FY23 (+681%).

05 · Capital Structure & Asset Utilization

0 Cr5000 Cr10000 Cr15000 Cr₹0×0.25×0.5×0.75×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr5000 Cr10000 Cr15000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-2000 Cr0 Cr2000 Cr4000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
————₹6,492.68 Cr₹8,814.04 Cr
EBITDA
————₹1,327.82 Cr₹1,911.57 Cr
₹29.00 Cr₹-102.00 Cr₹-64.00 Cr₹-17.00 Cr₹295.59 Cr₹493.61 Cr
Diluted EPS
————₹1.72₹2.8

Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Net income for Mar 2026 could not be checked against the company's own annual report: this page shows ₹493.61 Cr while the annual report gives ₹475.88 Cr (3.6% apart).

EBITDA for Mar 2026 could not be checked against the company's own annual report: this page shows ₹1,911.57 Cr while the annual report gives ₹1,164.45 Cr (39.1% apart).

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,802.00 Cr₹3,700.00 Cr₹9,462.00 Cr₹9,487.00 Cr₹10,390.00 Cr₹14,245.00 Cr
————₹2,572.77 Cr₹3,096.60 Cr
Stockholders' equity
₹2,378.00 Cr₹2,933.00 Cr₹5,456.00 Cr₹5,482.00 Cr₹5,931.00 Cr₹8,738.00 Cr

Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹-117.00 Cr₹-183.00 Cr₹95.00 Cr₹487.00 Cr₹1,231.00 Cr₹1,670.00 Cr
Investing cash flow
—————₹-2,724.80 Cr
₹-16.00 Cr₹604.00 Cr₹2,777.00 Cr₹-722.00 Cr₹-535.00 Cr₹1,201.00 Cr
Capital expenditure
₹-111.00 Cr₹-248.00 Cr₹-413.00 Cr₹-438.00 Cr₹-427.00 Cr₹-828.00 Cr
End cash position
—————₹973.30 Cr

Change in working capital, Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemNov 25–Dec 25(2Q)Mar 26Jun 26
Promoter17.57%17.55%17.53%
Public82.01%82.03%82.05%
Employee trusts0.42%0.42%0.42%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Lupin Limited₹92,244.53 Cr₹2,008.616.74.1123.8%0.29+23.9%+0.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Documents

Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.

LENSKART

Lenskart completes 1 year on NSE & BSE: Shares gain 86%, Mcap rises over Rs 59,000 crore – What's next?

Zee Business · 11 days ago

LENSKART

Lenskart Solutions Limited reports on IPO proceeds utilization for Q2 FY27

InvestyWise · 11 days ago